<DOC>
	<DOCNO>NCT02596100</DOCNO>
	<brief_summary>This single center open label randomize 4-period 2-sequence replicate crossover design study . A total 52 healthy subject randomize .</brief_summary>
	<brief_title>A Bioequivalence Study Compare Pharmacokinetics Two Betrixaban Formulations</brief_title>
	<detailed_description>Serial blood sample obtain PK evaluation .</detailed_description>
	<criteria>All inclusion criterion must satisfy within 30 day enrollment must document source document . A healthy man woman age 18 60 Has clinically significant finding medical history , physical examination , EKG vital sign Weighs &gt; 45 kg ( 99 lb . ) body mass index ( BMI ) &lt; 30 kg/m2 Agrees abstain alcohol consumption 48 hr prior dose duration study inhouse period Is nonsmoker light smoker ( equivalent five cigarette per day ) agree abstain smoke duration study inhouse period None exclusion criterion may present enrollment Known history ( include family history ) symptoms clinically significant bleeding ( i.e . bleeding required medical attention ) vascular malformation Major surgery , severe trauma bone fracture within 3 month first dose study drug plan surgery within 1 month last dose study drug History blood donation 500 mL within 3 month prior first dose study drug History alcohol abuse ( great 3 alcoholic beverage per day ) Positive screen drug abuse Positive serology test HIV , Hepatitis B C Has allergy sensitivity fXa inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>